JP2019533713A - ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法 - Google Patents

ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法 Download PDF

Info

Publication number
JP2019533713A
JP2019533713A JP2019524887A JP2019524887A JP2019533713A JP 2019533713 A JP2019533713 A JP 2019533713A JP 2019524887 A JP2019524887 A JP 2019524887A JP 2019524887 A JP2019524887 A JP 2019524887A JP 2019533713 A JP2019533713 A JP 2019533713A
Authority
JP
Japan
Prior art keywords
lalymph
cgmp
amount
dose
camp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533713A5 (enExample
Inventor
エイチ． クラップ，ルーシー
エイチ． クラップ，ルーシー
ピー． ビーハン，ドミニク
ピー． ビーハン，ドミニク
ダブリュー． アダムス，ジョン
ダブリュー． アダムス，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019533713A publication Critical patent/JP2019533713A/ja
Publication of JP2019533713A5 publication Critical patent/JP2019533713A5/ja
Priority to JP2022185917A priority Critical patent/JP2023029865A/ja
Priority to JP2025084398A priority patent/JP2025131627A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2019524887A 2016-11-10 2017-11-10 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法 Pending JP2019533713A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022185917A JP2023029865A (ja) 2016-11-10 2022-11-21 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法
JP2025084398A JP2025131627A (ja) 2016-11-10 2025-05-20 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US62/420,515 2016-11-10
US201762530533P 2017-07-10 2017-07-10
US62/530,533 2017-07-10
PCT/US2017/061116 WO2018089804A1 (en) 2016-11-10 2017-11-10 Methods of treating pah with combinations of ralinepag and other agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022185917A Division JP2023029865A (ja) 2016-11-10 2022-11-21 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法

Publications (2)

Publication Number Publication Date
JP2019533713A true JP2019533713A (ja) 2019-11-21
JP2019533713A5 JP2019533713A5 (enExample) 2020-12-17

Family

ID=60451197

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019524887A Pending JP2019533713A (ja) 2016-11-10 2017-11-10 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法
JP2022185917A Pending JP2023029865A (ja) 2016-11-10 2022-11-21 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法
JP2025084398A Pending JP2025131627A (ja) 2016-11-10 2025-05-20 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022185917A Pending JP2023029865A (ja) 2016-11-10 2022-11-21 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法
JP2025084398A Pending JP2025131627A (ja) 2016-11-10 2025-05-20 ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法

Country Status (10)

Country Link
US (1) US12377067B2 (enExample)
EP (1) EP3538154B1 (enExample)
JP (3) JP2019533713A (enExample)
KR (3) KR20240068077A (enExample)
CN (2) CN110691612B (enExample)
AU (2) AU2017357759A1 (enExample)
CA (1) CA3043283A1 (enExample)
IL (2) IL266518A (enExample)
MA (1) MA46750A (enExample)
WO (1) WO2018089804A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240068077A (ko) 2016-11-10 2024-05-17 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
WO2018160882A1 (en) 2017-03-01 2018-09-07 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
US12433865B2 (en) * 2018-05-16 2025-10-07 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
SI3897646T1 (sl) * 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Makitentan za zdravljenje pljučne arterijske hipertenzije
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CN118922402A (zh) 2022-02-15 2024-11-08 联合治疗公司 结晶前列环素(ip)受体激动剂及其用途
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042022A2 (en) * 2003-10-29 2005-05-12 Pfizer Limited Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
US20150025255A1 (en) * 2011-09-12 2015-01-22 Lung Biotechnology Inc. Process for preparing synthetic prostacyclins
WO2016065103A1 (en) * 2014-10-23 2016-04-28 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
RU2315746C2 (ru) 2001-08-09 2008-01-27 Оно Фармасьютикал Ко., Лтд. Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
WO2004072038A1 (en) 2003-02-10 2004-08-26 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
WO2006023844A2 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
EA200802213A1 (ru) 2006-05-09 2009-10-30 Химекуэст Фармасьютикалз, Инк. Способы лечения заболеваний крови
WO2009117095A1 (en) 2008-03-18 2009-09-24 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
NZ593002A (en) 2008-11-26 2013-08-30 Arena Pharm Inc Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
US8940891B2 (en) 2008-12-08 2015-01-27 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
EP2480526A1 (en) * 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
KR20150089087A (ko) * 2012-11-30 2015-08-04 인스메드 인코포레이티드 프로스타사이클린 조성물 및 이를 이용하기 위한 방법
MX2017009110A (es) * 2015-01-13 2017-11-09 Vivus Inc Terapia de combinacion para hipertension pulmonar.
KR20240068077A (ko) 2016-11-10 2024-05-17 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042022A2 (en) * 2003-10-29 2005-05-12 Pfizer Limited Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
US20150025255A1 (en) * 2011-09-12 2015-01-22 Lung Biotechnology Inc. Process for preparing synthetic prostacyclins
WO2016065103A1 (en) * 2014-10-23 2016-04-28 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUGS OF THE FUTURE, vol. 35, JPN6021042962, 2010, pages 9, ISSN: 0004827515 *
PROGRESS IN PEDIATRIC CARDIOLOGY, vol. 43, JPN6021042959, 13 May 2016 (2016-05-13), pages 71 - 80, ISSN: 0004827513 *
PROTEIN SCIENCE, vol. 25, JPN6021042960, 16 July 2016 (2016-07-16), pages 151 - 152, ISSN: 0004827514 *

Also Published As

Publication number Publication date
MA46750A (fr) 2019-09-18
CN119367341A (zh) 2025-01-28
AU2017357759A1 (en) 2019-06-06
IL323354A (en) 2025-11-01
AU2023263497B2 (en) 2025-09-18
KR20230021186A (ko) 2023-02-13
US20190321328A1 (en) 2019-10-24
EP3538154A1 (en) 2019-09-18
JP2023029865A (ja) 2023-03-07
CA3043283A1 (en) 2018-05-17
US12377067B2 (en) 2025-08-05
WO2018089804A1 (en) 2018-05-17
KR20200015439A (ko) 2020-02-12
AU2023263497A1 (en) 2023-11-30
IL266518A (en) 2019-07-31
CN110691612B (zh) 2024-11-08
CN110691612A (zh) 2020-01-14
WO2018089804A9 (en) 2018-06-21
KR20240068077A (ko) 2024-05-17
JP2025131627A (ja) 2025-09-09
EP3538154B1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
JP2025131627A (ja) ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法
O'callaghan et al. Treatment of pulmonary arterial hypertension with targeted therapies
US20050101608A1 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
CN103717219B (zh) 左心室舒张功能改善剂
Galiè et al. Emerging medical therapies for pulmonary arterial hypertension
US20080188497A1 (en) Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions
CA3250533A1 (en) METHODS AND COMPOSITIONS FOR TREATING EXCESS GLUCOCORTICOIDS
Hosoya et al. Protection of the cardiovascular system by imidapril, a versatile angiotensin‐converting enzyme inhibitor
Vachiery et al. Treprostinil for pulmonary hypertension
US20090023644A1 (en) Methods of using cgrp for cardiovascular and renal indications
RU2182002C2 (ru) Композиция с фиксированной дозой ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний
WO2005011727A1 (en) Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder
Ferreri et al. Renal COX-2, cytokines and 20-HETE: tubular and vascular mechanisms
US20100204249A1 (en) Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
Leuchte et al. Iloprost for idiopathic pulmonary arterial hypertension
US20100249103A1 (en) combination treatment
US20050059660A1 (en) Novel combination
FR2924345A1 (fr) Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
AU2008247451A1 (en) Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
Cheng New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation
EP4527385A1 (en) Il-6 and/or il-1? inhibitor
KR20050018330A (ko) 혈관장애의 치료 및 예방을 위한 디피리다몰,아세틸살리실산 및 안지오텐신 ⅱ 길항제의 용도
Clavecilla New insights into the treatment of pulmonary arterial hypertension
NO20053310L (no) Fremgangsmate og sammensetning til a behandle engstelse.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719